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Abstract
Purpose—Pre-clinical studies combining the proteasome inhibitor bortezomib with 
anthracyclines have shown enhanced anti-tumor activity. We therefore conducted a phase I trial of 
bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors.
Methods—Patients received bortezomib, 0.9-1.5 mg/m2, on days 1, 4, 8, and 11 of every 21-day 
cycle, along with PLD, 30 mg/m2, on day 4. The goals were to determine the dose limiting toxicity 
(DLT) and maximum tolerated dose (MTD), and to investigate pharmacokinetic and 
pharmacodynamic interactions of the combination.
Results—A total of 37 patients with 4 median prior therapies were treated. Frequent grade 1-2 
toxicities included fatigue, nausea, thrombocytopenia, anemia, neutropenia, constipation, 
myalgias, and peripheral neuropathy. DLTs included grade 3 nausea and vomiting in 1/6 patients 
receiving bortezomib at 1.2 mg/m2, and grade 3 nausea, vomiting, and diarrhea in 1/6 patients 
receiving bortezomib at 1.5 mg/m2. Grade 3 toxicities in later cycles included hand-foot 
syndrome, thrombocytopenia, anemia, neutropenia, nausea, diarrhea, and abdominal pain. Because 
of frequent dose-delays, dose-reductions, and gastrointestinal toxicity at the 1.4 and 1.5 mg/m2 
levels, bortezomib at 1.3 mg/m2 and PLD at 30 mg/m2 are recommended for further testing. 
Among 19 patients with breast cancer, four had evidence of a clinical benefit. Pharmacokinetic 
and pharmacodynamic studies did not show any significant interactions between the two drugs.
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Conclusions—A regimen of bortezomib, 1.3 mg/m2 on days 1, 4, 8, and 11 with PLD, 30 
mg/m2, on day 4 of a 21-day cycle, was safe in this study, and merits further investigation.
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Introduction
Bortezomib (VELCADE®; Millennium Pharmaceuticals, Inc. and Johnson & Johnson 
Pharmaceuticals Research & Development, L.L.C.) is a dipeptide boronic acid derivative 
that specifically inhibits the chymotrypsin-like activity of the proteasome (1), a large multi-
catalytic proteinase complex responsible for intracellular proteolysis. Proteasome blockade 
has anti-neoplastic effects through inhibition of several pathways, including growth 
signaling through the p44/42 mitogen-activated protein kinase (MAPK), cell cycling through 
stabilization of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1, survival signaling 
through Bcl-2 and nuclear factor kappa-B (NF-κB), and angiogenesis. Bortezomib has 
shown anti-tumor activity in a wide variety of preclinical models both in vitro and in vivo. In 
clinical trials, single-agent bortezomib has been effective against hematologic malignancies, 
most notably multiple myeloma (2, 3), for which bortezomib initially received regulatory 
approval, and several subtypes of non-Hodgkin lymphoma (4-6). Bortezomib has been 
approved by the FDA both for the treatment of multiple myeloma patients after at least one 
prior therapy and for the treatment of mantle cell lymphoma patients after at least one prior 
therapy. Some activity has also been seen in solid tumors, including prostate cancer (7), non-
small cell lung cancer (8), renal cell carcinoma (9), and ovarian cancer (10). The most 
common regimen in hematological malignancies uses bortezomib 1.3 mg/m2 on days 1, 4, 8, 
and 11 of a 21-day cycle, while the maximum tolerated dose (MTD) in solid tumor patients 
has been defined at 1.50 or 1.56 mg/m2 (10, 11). Common toxicities include gastrointestinal 
symptoms, fatigue, thrombocytopenia, and sensory neuropathy.
Modulation of proteasome function has been shown to enhance chemosensitivity, and to 
overcome chemoresistance. By inducing phosphorylation and cleavage of Bcl-2, preventing 
chemotherapy-mediated activation of NF-κB, and inhibiting normal maturation of P-
glycoprotein, proteasome inhibitors have been shown to have additive to synergistic activity 
in combination with standard chemotherapeutics such as CPT-11, gemcitabine, and taxanes 
(12, 13). Bortezomib also suppresses DNA damage repair pathways (14), thereby sensitizing 
tumor cells to DNA damaging agents like anthracyclines. Pegylated liposomal doxorubicin 
(PLD) has documented activity against a number of tumor types including breast cancer and 
ovarian cancer. In a phase II study of PLD at 45-60 mg/m2 given every 3 to 4 weeks to treat 
anthracycline-naïve breast cancer, the overall response rate was 31% (15). Response rates 
are lower in patients with anthracycline pretreated breast cancer (16), but cumulative dosing 
of PLD may be less cardiotoxic than parent doxorubicin (17). Preclinical studies in a number 
of model systems have shown that doxorubicin and bortezomib have synergistic activity, 
and can overcome prior anthracycline resistance in vitro (18, 19). Further, doxorubicin can 
suppress proteasome inhibitor-mediated induction of anti-apoptotic factors, such as MAPK 
phosphatase-1 (19). Finally, the combination of bortezomib with pegylated liposomal 
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doxorubicin (PLD) has been shown to have enhanced activity in vivo in a model of human 
breast cancer (19).
Here we report the results of a phase I trial of bortezomib and PLD, which was designed to 
determine the maximum tolerated dose (MTD) of bortezomib when given with a fixed dose 
of PLD. Additional study objectives were to explore the possibility that there were 
pharmacokinetic and pharmacodynamic interactions between the two agents. We have 
previously reported results of a study of this combination in patients with hematologic 
malignancies (20). Patients with solid tumors were evaluated separately with the hypothesis 
that toxicities of the regimen, specifically myelosuppression and neuropathy, might be 
different given differences in disease involvement and prior therapies between the two 
groups. In the present study we show that bortezomib, 1.3 mg/m2 on days 1, 4, 8, and 11, 
along with PLD at 30 mg/m2 on day 4, can be safely administered to patients with solid 
tumors on an every 21-day schedule. Moreover, interesting evidence of anti-tumor activity 
in patients with advanced breast carcinoma was seen, suggesting this regimen holds promise 
and should be investigated further in this patient population.
Patients and Methods
Eligibility
Patients with histologically or cytologically confirmed solid tumor malignancies refractory 
to at least one conventional therapy, or for whom no standard therapy existed, were 
candidates for this study. Eligibility criteria included age >18 years; Karnofsky performance 
status >60%; a life expectancy of ≥8 weeks; no major surgery, radiotherapy, or 
chemotherapy within 21 days of study entry; adequate hematopoietic (hemoglobin >8.0 
g/dL, ANC >1500/μL, and platelets >50,000/μL), hepatic (total bilirubin <1.2 mg/dL and 
transaminases <2.5 times the upper limits of normal), and renal function (creatinine <2.5 
mg/dL); adequate cardiovascular function as defined by no evidence of ischemia on 
electrocardiography (ECG) and a left ventricular ejection fraction (LVEF) >45%; not 
pregnant or nursing and amenable to using appropriate contraception; and no other 
coexisting medical problems of sufficient severity to limit full compliance with the study or 
which could cause undue risk. Patients were ineligible if they had a prior cumulative 
exposure to doxorubicin >400 mg/m2, or hypersensitivity to PLD, or had uncontrolled active 
infections, or were known to be human immunodeficiency virus sero-positive, or have active 
viral hepatitis. All patients gave written, informed consent according to federal and 
institutional guidelines before treatment.
Trial Design
This was a phase I trial in which bortezomib was escalated from a starting dose of 0.90 
mg/m2 as an intravenous bolus on days 1, 4, 8, and 11 of each 3-week cycle, while PLD was 
held constant at 30 mg/m2 as an intravenous infusion on day 4. A modified Fibonacci 
escalation was used, with bortezomib dose steps of 0.90, 1.05, 1.20, 1.30, 1.40, and 1.50 
mg/m2.
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A standard “3+3” dose escalation scheme was employed in which a cohort of 3 patients was 
entered sequentially, and if none developed a dose limiting toxicitiy (DLT) then the next 
cohort was enrolled at the next higher bortezomib dose level while maintaining the same 
PLD dose. All patients in a given cohort were required to have completed one 3-week cycle 
of therapy before the next cohort was started. If one of the three patients in a cohort had a 
DLT, 3 additional patients were enrolled at that dose level. Among the 3 additional patients 
enrolled in a cohort, if no DLTs occurred escalation to the next dose level proceeded. If 2 of 
3 to 6 patients in a cohort had a DLT, the dose level exceeded MTD, which was defined as 
the highest dose level at which the incidence of DLTs was < 33%. In this trial, dose delays 
and dose reductions, which precluded therapy with assigned drug doses, also impacted the 
final assessment of a recommended dose, as discussed below. Additional patients were 
accrued once the recommended dose had been identified to confirm safety and obtain 
additional experience.
The NCI Common Toxicity Criteria Version 2.0 was used to characterize toxicity. Patients 
were evaluated weekly. DLT was defined on the first cycle as a ≥grade 3 non-hematological 
toxicity and/or ≥grade 4 hematological toxicity with the following exceptions: nausea, 
vomiting, and diarrhea were only considered DLTs if they did not respond to antiemetics 
and/or anti-diarrheals, recurrent grade 2 or higher hand-foot syndrome (HFS; formerly 
palmar-plantar erythrodysesthesia) was considered a DLT, grade 4 neutropenia was a DLT 
only if accompanied by fever or lasting >5 days, and a 2 week or greater dose delay was 
considered a DLT.
Additionally, all patients had a pre-study assessment of left ventricular ejection fraction, and 
those patients who had total anthracycline exposure of greater than 300 mg/m2 had serial 
assessments every 4 cycles thereafter.
Response Criteria
Tumor assessments were performed every 2 cycles, and response was evaluated using the 
RECIST criteria (21).
Drug Administration
Bortezomib was provided as a sterile, lyophilized powder in vials with mannitol, which was 
reconstituted with normal saline to a drug concentration of 1 mg/mL, and administered by 
intravenous push over 3-5 seconds on treatment days. PLD from commercial stock was 
prepared as per the package insert and administered as a 60-90 minute infusion one-hour 
after bortezomib administration. Day 4 was chosen to allow evaluation of proteasome 
inhibition on days 1 and 4 in the presence of bortezomib alone, and on days 8 and 11 with 
both drugs present, allowing each patient to serve as their own control. Treatment days 
could be changed by up to 24-hours providing there was a ≥72-hour span between 
consecutive bortezomib doses.
Pharmacodynamics and Pharmacokinetics
Blood samples were collected at baseline and 1 hour after bortezomib for measurement of 
20S proteasome activity during cycle 1. Since bortezomib rapidly exits the intravascular 
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compartment, standard pharmacokinetic parameters do not adequately guide dosing, and a 
pharmacodynamic assay measuring the percentage proteasome inhibition was used to 
provide a more relevant characterization (22). PLD pharmacokinetic studies were performed 
from blood samples collected at baseline, and at 1, 24, and 96 hours, and 7, 14, and 18 days 
after PLD administration. Doxorubicin released from the liposomal preparation was 
evaluated by high-performance liquid chromatography (20, 23 and 25). Compartmental and 
non-compartmental analysis was conducted using WinNonlin® Professional software, 
version-3.2 (Pharsight Corporation; Mountain View, CA).
Results
Patient Characteristics
Thirty seven patients (median age 54), 29 of whom were women and 19 of whom had breast 
cancer (Table 1) were enrolled and treated between January 2002 and February 2006 and 
treated concurrently with a separate cohort of patients with hematologic malignancies who 
were on a different arm of this trial(20). Most of the patients were heavily pretreated, and 
the median number of prior therapies was four. Six dose levels were evaluated (Table 2), 
and a total of 117 cycles of bortezomib/PLD therapy were administered, with a median of 
two cycles per patient (range 1-10 cycles).
Adverse Events
Thirty four (92%) patients completed at least one cycle and were evaluable for toxicity, and 
the most frequent adverse events included grade 1-2 fatigue, nausea, thrombocytopenia, 
anemia, neutropenia, constipation, myalgias, and peripheral neuropathy (Table 3). DLTs in 
cycle 1 (Table 2) were nausea and vomiting in 1 of 6 patients treated with bortezomib at 1.2 
mg/m2, and nausea, vomiting, and diarrhea in 1 of 6 patients treated with bortezomib at 1.5 
mg/m2. Other treatment-related grade 3 toxicities seen in later cycles included HFS, 
thrombocytopenia, anemia, neutropenia, nausea and diarrhea, and abdominal pain. Grade 3 
and 4 adverse events regardless of attribution seen by dose level are shown in Table 4, and 
included 4 episodes each of anemia, thrombocytopenia and neutropenia, as well as 
transaminitis (4), nausea (4), constipation (3), diarrhea (3), fatigue (3), peripheral 
neuropathy (3) and myalgia (1), vomiting (3) and 5 episodes of thrombosis (discussed 
below). Hematologic toxicity was in general only mild to moderate, with a median nadir 
ANC of 2600 (range 700-9100) and a median nadir platelet count of 127,000 (range 23-365) 
across all dose levels. There was no dose-related trend but myelosuppression was most 
severe in the highest dose level, with a median nadir ANC of 1800 (range 600-4000) and 
median nadir platelets 86, 000 (range 26,000-168,000). Thrombocytopenia of moderate 
severity occurred at bortezomib dose levels of 1.2 mg/m2 and above.
Peripheral neuropathy and myalgia were observed in 28% and 20% of cycles, respectively. 
Patients affected typically described an aching burning pain in their lower extremities which 
was constant. These symptoms, particularly the myalgia, appeared to be related to 
cumulative bortezomib dose, occurring primarily in patients treated with doses of at least 1.2 
mg/m2 (15 of 17 patients affected) who had received 2-4 cycles, with severity increasing 
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with subsequent cycles. These symptoms were managed with NSAIDs, opioids, gabapentin, 
and pyridoxine with variable success.
Five patients developed venous thromboses while on study, including two each with 
pulmonary emboli and deep vein thrombosis, and one with superior mesenteric vein 
thrombosis. In all cases, the investigators felt that the thrombotic events were related to the 
underlying disease and other risk factors. One patient who had previously received 300 
mg/m2 doxorubicin as adjuvant treatment of breast cancer three years prior had an 
asymptomatic drop in ejection fraction to 35% after 5 cycles of therapy, which improved to 
45% without intervention within 2 weeks of discontinuing treatment. Three other patients 
met criteria for serial evaluations of LVEF during the study, and none experienced a 
significant decline below baseline.
According to the initial protocol definition of MTD, bortezomib at 1.50 mg/m2 and PLD at 
30 mg/m2 met these criteria. Further bortezomib dose escalation was not pursued since this 
would have exceeded both the single-agent MTD of 1.5 mg/m2 (10), and the 1.3 mg/m2 dose 
which had been approved for myeloma. Furthermore, among six patients receiving 
bortezomib at 1.5 mg/m2, three had grade 3 gastrointestinal toxicity during subsequent 
cycles, and three required first cycle delays for grade 2 neutropenia. Therefore, this level 
was considered higher than tolerable, and additional patients were enrolled at the next lower 
dose levels. Among six patients receiving bortezomib at 1.4 mg/m2, three required first 
cycle dose delays and two needed dose reductions by cycle 3. Due to the frequent need for 
dose-delays and dose-reductions, and gastrointestinal toxicity in later cycles at the 1.4 and 
1.5 mg/m2 levels, bortezomib at 1.30 mg/m2 and PLD at 30 mg/m2 were chosen for further 
testing.
Pharmacokinetics and Pharmacodynamics
Bortezomib pharmacodynamics was evaluated using an ex vivo assay of the 20S-proteasome 
(22) during the first cycle of therapy in 24 patients. The mean percent inhibition 1-hour after 
each bortezomib dose compared with the pre-treatment baseline (Figure 1A) was 
comparable across dose levels from 1.05 to 1.50 mg/m2, and no significant difference was 
noted between days 1 and 4. To evaluate whether PLD would impact upon bortezomib-
induced effects, proteasome inhibition was compared on days 1 and 4, in the presence only 
of bortezomib, with days 8 and 11, when bortezomib and PLD were present (Figure 1B). 
Across all dose levels, mean proteasome inhibition on days 8 and 11, 67.8%, was not 
different than that measured on days 1 and 4, 67.0%, (p=0.65). The effect of bortezomib and 
PLD on the specific activity of the chymotryptic proteasome protease was also evaluated. 
Specific activity decreased with bortezomib (Figure 1C), with baseline and 1-hour post-
therapy activities being comparable across the 1.05-1.50-mg/m2/dose range. Finally, the 
mean specific activity at baseline and 1 hour after dosing was studied on days 1 and 4, and 
compared with days 8 and 11 (Figure 1D). This activity declined in both situations by 
approximately the same amount, 0.30 on days 1 and 4, versus 0.26 on days 8 and 11. Thus, 
the bortezomib-induced decline of the specific activity of the proteasome did not depend on 
whether PLD was present.
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Pharmacokinetic parameters of PLD in the presence of bortezomib were determined by 
detection of doxorubicin released from pegylated liposomes (23, 24) in 32 patients. The 
peak plasma concentration of doxorubicin after single dose administration, area under the 
concentration-time curve, total plasma body clearance, volume of distribution, and half-life 
were determined at each dose level. For the entire cohort, the median half life (t1/2) for PLD 
was 69.75 hours (range 33.77-110.54). Maximum plasma concentration (Cmax) was 20.5 
μg/mL (range 13.53-42.23), area under the concentration–time curve (AUC) was 2138.5 
(905-5147.8), and clearance 26.25 mL/hr (9.79-62.32).
Responses
Among the 19 patients with breast cancer, one achieved a near complete remission of 
cutaneous disease, a second had a partial response of liver metastases (Figure 2), a third 
experienced resolution of a large malignant effusion and stable adenopathy for 5 cycles, and 
a fourth attained stable disease in liver metastases for 5 months. The patient with a partial 
response in liver metastases remained on study for 11 months, but eventually discontinued 
because of fatigue and logistical constraints. She subsequently progressed through several 
other treatments, and when bortezomib was approved she was retreated with the 
combination and again recaptured a response/clinical benefit. This patient as well as the 
other patient with partial response were treated on dose level 6 (1.5 mg/m2) but both 
required dose reduction to 1.3 mg/m2 for toxicity. The two other responders were treated at 
1.05 mg/m2 and 1.4 mg/m2 levels respectively. Three additional patients with other tumor 
types in this heavily pre-treated solid tumor population had stable disease for greater than 4 
cycles, including one each with renal cell carcinoma, adrenal cortical carcinoma, and non-
small cell lung cancer.
Discussion
Bortezomib was the first proteasome inhibitor to enter clinical development and has been 
approved for use in multiple myeloma and mantle cell non-Hodgkin lymphoma. Preclinical 
studies have shown augmentation of activity when bortezomib was administered with 
anthracyclines. Therefore, this phase I study was undertaken to evaluate the maximum 
tolerated dose of bortezomib given on a day 1, 4, 8, 11 schedule in combination with PLD 
every 3 weeks in patients with solid tumors. According to the protocol-specified definition, 
bortezomib at 1.50 mg/m2 with PLD met the criteria for MTD. However, extensive 
additional information is now available from other studies of bortezomib and the dose of 1.3 
mg/m2 on this schedule is now approved in multiple myeloma. To define a regimen that 
could be administered with a lower likelihood of dose delays and dose reductions, the 
recommended dose for phase II trials of the combination is bortezomib 1.3 mg/m2 and PLD 
30 mg/m2 day 4 of a 21 day cycle.
In this study the most frequent toxicities were fatigue, nausea, myelosuppression, peripheral 
neuropathy and diarrhea. This is similar to the toxicity profile reported for the single agent 
in other studies (10, 11, 25). However, neutropenia was more severe and more frequent in 
our study, likely due to the concomitant PLD, or to differences in the patient populations and 
prior treatments. HFS was seen in this combination study but has not been reported with the 
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single agent bortezomib to our knowledge. This also is likely attributable to the PLD use. It 
appears that hematologic toxicity and gastrointestinal toxicity may be dose-related, 
particularly in the highest three dose levels, and that HFS, neuropathy and myalgia are 
related to cumulative dose.
In the present study peripheral neuropathy affected 17 of 37 or 46% of patients and 
complicated 28% of cycles. This incidence is somewhat higher than that seen and reported 
previously. Combined data from two recent trials in myeloma patients (26) has shown 
treatment emergent peripheral neuropathy in 37% of patients treated at 1.3 mg/m2. Perhaps 
we have a higher incidence in this study because twelve of the 37 patients on the study were 
treated at doses higher that 1.3. Furthermore, 18 of 37 had prior treatment with a taxane or 
platinum agent, whereas 36% had previous platinum in the myeloma studies and none had 
taxanes. Dose reduction guidelines for neuropathy now exist for bortezomib treatment (26) 
that may help in managing patients who develop this toxicity.
We have previously reported our phase I trial of this combination in patients with 
hematologic malignancies (20) and found a similar toxicity profile despite the differences in 
underlying disease and prior treatments. Furthermore, subsequent evaluation of this 
combination in patients with myeloma has shown marked efficacy, and phase III evaluation 
has shown a better response rate, response quality, TTP, PFS, and OS in patients receiving 
Doxil/Velcade compared to standard therapy .(27)
The preliminary evidence of anti-breast cancer activity seen in this phase I study is 
promising and intriguing. A phase II trial to determine the efficacy of this combination in 
metastatic breast cancer has begun accrual. As described previously there is promising 
preclinical data and biologic rationale to evaluate this combination in breast cancer (19). 
However single agent PLD has shown only modest activity in breast cancer (15) and 
bortezomib as a single agent has not shown significant activity in patients with breast cancer 
(28). Of interest, two of the four most significant responses seen in our study were in women 
who had not previously been treated with anthracyclines. Therefore, it is unclear whether the 
potential efficacy of the combination is mediated through direct activity or modulation of 
anthracycline resistance.
A number of other combinations of bortezomib and chemotherapy are currently being 
investigated in clinical trials in patients with solid tumors. Preliminary results from an 
ongoing study of bortezomib and docetaxel in patients with anthracycline pre-treated breast 
cancer have been presented showing 6 of 9 patients with partial responses and an MTD had 
not yet been reached (29). By contrast, Messersmith and colleagues have completed a phase 
I study of bortezomib with docetaxel using a different schedule and an MTD was defined at 
the relatively low dose of 0.8 mg/m2 bortezomib in combination with 25 mg/m2 docetaxel 
(30). Aghajanian and colleagues have conducted a phase I study of bortezomib combined 
with carboplatin in patients with ovarian cancer, and found that diarrhea, constipation and 
neuropathy were dose limiting at the 1.5 mg/m2 dose level. Like ours, her recommended 
dose for further study was also 1.3 mg/m2 bortezomib in combination with a carboplatin 
area under the curve of 5. Carboplatin had no effect on bortezomib pharmacodynamics in 
this study.
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Recently, Ma and colleagues have published their investigation of bortezomib combined 
with paclitaxel and carboplatin on two different schedules. In this study the sequence in 
which bortezomib was given on days 1, 4, and 8 with paclitaxel and carboplatin on day 2 
seemed to be better tolerated and more effective that the sequence in which the 
chemotherapy was given the day before the bortezomib (31). However, in the Messersmith 
study above, in which the day 1 chemotherapy and day 2 bortezomib dosing schedule also 
resulted in a lower MTD than expected, docetaxel pharmacokinetics were performed at two 
time points and the parameters were not altered by the presence of bortezomib on day 5 (30). 
In our study the bortezomib and PLD were given together on day 4 with the PLD given one 
hour after the bortezomib. Doxorubicin pharmacokinetic parameters were not significantly 
different than reported single agent values. Further trials assessing sequence effect are 
underway, and additionally other schedules are under investigation (32).
Doxorubicin kinetics were assessed using a limited sampling scheme and parameters were 
not significantly different than published values for PLD alone (17). Furthermore, there was 
no significant trend detected for a change in these parameters with increasing bortezomib 
dose . These findings suggest that the presence of bortezomib does not alter the 
pharmacokinetics of PLD. Because bortezomib rapidly exits the intravascular compartment, 
the pharmacodynamic assay for 20S inhibition was evaluated rather than standard 
pharmacokinetic parameters. The percent proteasome inhibition across dose levels evaluated 
in this study (67%) is consistent with that reported in other studies of single agent 
bortezomib (10), and does not appear to be impacted by concomitant PLD treatment, as 
shown in Figure 1. Furthermore, change in specific activity was no different with and 
without PLD as shown by comparing the slopes in Figure 1D. Therefore we conclude that 
concomitant doxorubicin is not likely to alter the pharmacodynamic effect of bortezomib.
In conclusion, we have found that in this population of heavily pretreated patients with solid 
tumors, the combination of bortezomib at 1.3 mg/m2 days 1, 4, 8, 11 and PLD 30 mg/m2 day 
4 every 3 weeks is tolerable and worthy of further study. Frequent toxicities included fatigue 
nausea, myelosuppression, diarrhea, and peripheral neuropathy/myalgia. Dose limiting 
toxicities were nausea, vomiting, and diarrhea. One patient had a reversible decline in 
ejection fraction. Studies are ongoing to better define the nature and optimal treatment of 
cumulative toxicities such as neuropathy. Future studies of this combination should be 
attentive to potential risk for thrombosis. We found no pharmacokinetic or 
pharmacodynamic interaction between the drugs. Finally, evidence of activity in metastatic 
breast cancer has prompted a phase II trial which is now ongoing.
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In this phase I study in 37 patients with refractory solid tumors, a regimen of bortezomib, 
1.3 mg/m2 on days 1, 4, 8, and 11 with PLD, 30 mg/m2, on day 4 of a 21-day cycle, was 
safe and merits further investigation. No pharmacokinetic or pharmacodynamic 
interactions were appreciated and activity was seen in patients with breast cancer.
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Pharmacodynamics of bortezomib(B) and PLD. (A) Inhibition of the chymotryptic activity 
of the 20S proteasome by B is shown as a function of the administered dose level (in 
mg/m2). The mean percentage inhibition 1 hour after each dose compared to the 
pretreatment baseline is shown for days 1 and 4. All data presented are from the first cycle 
of therapy. (B) The mean 20S proteasome inhibition one hour after each dose B alone on 
days 1 and 4 is compared to mean inhibition on days 8 and 11, when both B and PLD were 
present. (C) Specific activity of the chymotrypsin like proteasome protease is shown at 
baseline and one hour after bortezomib treatment on day 1 as a mean for each dose level. 
The units for specific activity are picomoles of fluorescent chromophore released per second 
per milligram of total protein. (D) Mean proteasome activity is shown at baseline and one 
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hour after dosing with either bortezomib alone (days 1 and 4) or bortezomib in the presence 
of PLD (days 8 and 11).
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Figure 2a. A patient with cutaneous metastases had dramatic and rapid response shown here 
from cycle 1 to cycle 3 with time to progression over 4 months.
Figure 2b. A patient with breast cancer hepatic metastases had partial response in her hepatic 
disease with time to progression 11 months.
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Table 1
Patient Characteristics
No. of patients 37
Sex
    Female 29
    Male 8
Age, years
    Mean 54
    Range 35-75
Race
    African American 6
    Caucasian 29
    Hispanic 1
    Other 1
Diagnoses
    Breast Cancer 19
    Lung Cancer 4
    TCC Bladder 3
    Head and Neck 3
    Adrenocortical 1
    Sarcoma 1
    Colorectal 2
    Primary Peritoneal 1
    Ovarian 1
    Kidney 1
    Uterine Carcinosarcoma 1
Karnofsky performance status
    100 11
    90-80 17
    70-60 9
Prior therapy
    Chemotherapy 37
    Anthracycline 20
Median number of regimens (range) 4 (1-11)
    Radiation therapy 27
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Table 2
Dose Escalation and DLTs
Bortezomib Dose level (mg/m2) Number evaluable pts Number DLT First cycle dose delay Dose reduction
0.9 3
1.05 3
1.2 6 1 NV 1
1.3 10
1.4 6 3 3
1.5 6 1 NV D 3 3
DLT= Dose limiting toxicity, N = nausea, V = vomiting, D= diarrhea
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Table 3
Most Frequent Adverse Events (Occurring in >10% cycles) (N=117)
Adverse Event Number (%) cycles 
affected, any grade 
(N=117)
Number (% ) cycles 
grade 3
Number (%) cycles 
grade 4
Number (%) patients 
affected, any grade (N 
= 37)
Fatigue 92 (79) 2 1 32 (86)
Nausea 73 (62) 4 0 30 (81)
Thrombocytopenia 46(39) 8 0 18 (49)
Anemia 37 (32) 4 1 19 (51)
Constipation 35 (30) 4 0 17 (46)
Peripheral Neuropathy 33 (28) 3 0 17 (6)
Neutropenia 31 (26) 6 1 13 (35)
Myalgia 24 (21) 2 0 10 (27)
Lymphopenia 24 (21) 7 0 9 (24)
Diarrhea 20 (17) 3 0 11 (30)
Anorexia 15 (13) 0 0 10 (27)
Headache 14 (12) 1 0 13 (35)
Dyspnea 13 (11) 2 0 10 (27)
Rash 13 (11) 1 0 8 (22)
Reflux 13 (11) 0 0 8 (22)
Palmar-Plantar 12 (10) 1 0 7 (19)
Erythrodysesthesia/Han d-Foot Syndrome
Insomnia 12 (10) 0 0 5 (14)
Vomiting 12 (10) 3 0 8(22)
Abdominal pain 12 (10) 1 0 6( 16)
Fever 10(8) 1 0 6 (16)
Transaminitis 10 (8) 4 0 7 (19)
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Table 4
Grade 3-4 Adverse Events Occurring in at Least Two Patients by Dose Level
Adverse_Event .90 (n=3) 1.05 (n=3) 1.20 (n=6) 1.30 (n=9) 1.40 (n=6) 1.50 (n=6)
Anemia 2 1 1
Elevated LFTs 2 2
Lymphopenia 1 2 1
Nausea 1 3
Neutropenia 1 1 2
Thrombocytopenia 1 1 2
Constipation 3
Diarrhea 3
Fatigue 1 1 1
Peripheral neuropathy 1 2
Vomiting 1 2
Coagulopathy 1 1




Pulmonary emboli 1 1
N number of patients evaluable for toxicity.
All cycles. Adverse events regardless of attribution
LFT= liver function tests, DVT= deep vein thrombosis , LE= lower extremity
Cancer Chemother Pharmacol. Author manuscript; available in PMC 2015 February 01.
